Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Outlook 2022

Annual industry ranking and forecast

The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize

Industry Leaders Back At The Wheel Are Driving Health Care Transformation

Executive Summary

Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.

You may also be interested in...



Minute Insight: Viz.ai Raises $100M To Expand AI-Based Platform To Detect Diseases, Coordinate Care In Hospitals

The latest funding round, led by Tiger Global Management and Insight Partners, values the company at $1.2bn.

Deepak Nath Leaves Siemens To Become Smith & Nephew's New CEO

Deepak Nath will take over as Smith & Nephew’s new CEO on 1 April, joining the orthopedics and wound care company after four years as president of Siemens Healthineers’ diagnostics business. Smith & Nephew’s current CEO Roland Diggelmann is stepping down by mutual agreement.

JPM 2022: Abbott, iRhythm, Novocure, Zimmer Biomet

The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT144862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel